Lifitegrast - Optifye Therapeutics
Alternative Names: Lifitegrast OADLatest Information Update: 20 Apr 2022
At a glance
- Originator Optifye Therapeutics
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Benzofurans; Eye disorder therapies; Isoquinolines; Propionic acids; Skin disorder therapies; Small molecules; Sulfones
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Dry eyes
Most Recent Events
- 04 Apr 2022 Early research in Dry eyes in Switzerland (Ophthalmic) before April 2022 (Optifye Therapeutics pipeline, April 2022)